REGENXBIO Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and Tax
REGENXBIO Inc. (RGNX) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and Tax of $3.69 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax · last filed 2025-03-13
- REGENXBIO Inc. oci, debt securities, available-for-sale, gain (loss), before adjustment and tax for the quarter ending 2023-12-31 was $2.98M, a 4.52% increase year-over-year.
- REGENXBIO Inc. oci, debt securities, available-for-sale, gain (loss), before adjustment and tax for the quarter ending 2023-09-30 was $2.69M.
- REGENXBIO Inc. oci, debt securities, available-for-sale, gain (loss), before adjustment and tax for the quarter ending 2023-06-30 was $1.52M.
- REGENXBIO Inc. oci, debt securities, available-for-sale, gain (loss), before adjustment and tax for the quarter ending 2023-03-31 was $3.78M.
- REGENXBIO Inc. oci, debt securities, available-for-sale, gain (loss), before adjustment and tax for fiscal 2024 was $3.69M, a 66.39% decline from fiscal 2023.
- REGENXBIO Inc. oci, debt securities, available-for-sale, gain (loss), before adjustment and tax for fiscal 2023 was $10.97M.
- REGENXBIO Inc. oci, debt securities, available-for-sale, gain (loss), before adjustment and tax for fiscal 2022 was -$12.83M.
- REGENXBIO Inc. oci, debt securities, available-for-sale, gain (loss), before adjustment and tax for fiscal 2021 was -$2.21M.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2024-12-31 | $3.69M 10-K · filed 2025-03-13 | |||
| 2023-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $5.67M derived: sum of 2 quarters · filed 2025-03-13 | $7.19M derived: sum of 3 quarters · filed 2025-03-13 | $10.97M 10-K · filed 2025-03-13 |
| 2023-09-30 | $2.69M 10-Q · filed 2023-11-08 | $4.21M derived: sum of 2 quarters · filed 2023-11-08 | $7.99M 10-Q · filed 2023-11-08 | $10.84M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $1.52M 10-Q · filed 2023-08-02 | $5.30M 10-Q · filed 2023-08-02 | $8.16M derived: sum of 3 quarters · filed 2025-03-13 | $4.67M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $3.78M 10-Q · filed 2023-05-03 | $6.63M derived: sum of 2 quarters · filed 2025-03-13 | $3.14M derived: sum of 3 quarters · filed 2025-03-13 | $328.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$638.00K derived: sum of 2 quarters · filed 2025-03-13 | -$3.45M derived: sum of 3 quarters · filed 2025-03-13 | -$12.83M 10-K · filed 2025-03-13 |
| 2022-09-30 | -$3.49M 10-Q · filed 2023-11-08 | -$6.31M derived: sum of 2 quarters · filed 2023-11-08 | -$15.69M 10-Q · filed 2023-11-08 | -$16.97M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$2.81M 10-Q · filed 2023-08-02 | -$12.19M 10-Q · filed 2023-08-02 | -$13.48M derived: sum of 3 quarters · filed 2024-02-27 | -$13.51M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$9.38M 10-Q · filed 2023-05-03 | -$10.66M derived: sum of 2 quarters · filed 2024-02-27 | -$10.70M derived: sum of 3 quarters · filed 2024-02-27 | -$10.58M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$1.31M derived: sum of 2 quarters · filed 2024-02-27 | -$1.20M derived: sum of 3 quarters · filed 2024-02-27 | -$2.21M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$30.00K 10-Q · filed 2022-11-03 | $83.00K derived: sum of 2 quarters · filed 2022-11-03 | -$925.00K 10-Q · filed 2022-11-03 | -$1.55M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $113.00K 10-Q · filed 2022-08-03 | -$895.00K 10-Q · filed 2022-08-03 | -$1.52M derived: sum of 3 quarters · filed 2023-02-28 | -$2.00M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$1.01M 10-Q · filed 2022-05-04 | -$1.63M derived: sum of 2 quarters · filed 2023-02-28 | -$2.12M derived: sum of 3 quarters · filed 2023-02-28 | -$788.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$623.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$1.11M derived: sum of 2 quarters · filed 2023-02-28 | $220.00K derived: sum of 3 quarters · filed 2023-02-28 | -$565.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | -$487.00K 10-Q · filed 2021-11-02 | $843.00K derived: sum of 2 quarters · filed 2021-11-02 | $58.00K 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $1.33M 10-Q · filed 2021-08-09 | $545.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$785.00K 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $885.00K 10-K · filed 2022-03-01 | |||
| 2018-12-31 | -$5.00K 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |